Clinical Medicine, MiBioPath Group, Universidad Católica San Antonio de Murcia, ES-30107 Guadalupe, Murcia, Spain.
Acta Derm Venereol. 2019 Nov 1;99(12):1078-1084. doi: 10.2340/00015555-3305.
The aim of this 12-week randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of a probiotic mixture in the reduction of psoriasis severity. Ninety 18-70-year-old adults with plaque psoriasis were randomized into probiotic and placebo groups. At 12-week follow-up, 66.7% of patients in the probiotic group and 41.9% in the placebo group showed a reduction in Psoriasis Area and Severity Index of up to 75% (p < 0.05). A clinically relevant difference was observed in Physician Global Assessment index: 48.9% in the probiotic group achieved a score of 0 or 1, compared with 30.2% in the placebo group. The results of follow-up 6 months after the end of the study showed a lower risk of relapse after the intake of the probiotic mixture. Analysis of gut microbiota confirmed the efficacy of the probiotic in modulation of the microbiota composition.
本为期 12 周的随机、双盲、安慰剂对照试验旨在确定益生菌混合物在减轻银屑病严重程度方面的疗效和安全性。90 名 18-70 岁的斑块状银屑病患者被随机分为益生菌组和安慰剂组。在 12 周随访时,益生菌组 66.7%的患者和安慰剂组 41.9%的患者达到了银屑病面积和严重程度指数(PASI)下降 75%(p < 0.05)。在医生整体评估指数中观察到了临床相关差异:益生菌组 48.9%的患者评分达到 0 或 1,而安慰剂组为 30.2%。研究结束后 6 个月的随访结果显示,摄入益生菌混合物后复发的风险较低。肠道微生物组分析证实了益生菌对微生物组成的调节作用。